Literature DB >> 17444583

Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis.

Kiyofumi Hagiwara1, Takeo Sato, Shoko Takagi-Kobayashi, Shunsuke Hasegawa, Nayumi Shigihara, Osamu Akiyama.   

Abstract

A 70-year-old woman with a 6-year history of seropositive rheumatoid arthritis (RA) and asymptomatic interstitial lung disease (ILD) began taking etanercept for ongoing arthritis despite treatment with methotrexate (MTX) and bucillamine. MTX was discontinued before introduction of etanercept. She developed lung injury 8 weeks after starting etanercept. Etanercept was discontinued and oral prednisolone 40 mg/day was begun, and her clinical findings gradually improved. Lung injury, although rare, is a recently noticed, potentially fatal adverse effect of all 3 licensed biological anti-tumor necrosis factor (TNF) agents. We recommend caution in the use of anti-TNF agents in elderly RA patients with preexisting ILD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17444583

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  19 in total

1.  A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα.

Authors:  Takuya Masuda; Atsushi Yoshida; Fumiaki Ueno; Shintaro Hara; Haruaki Nabeta; Shotaro Umezawa; Mayuki Shirai; Yoshihide Morikawa; Toshio Morizane; Yutaka Endo; Toshifumi Hibi
Journal:  Inflamm Intest Dis       Date:  2019-03-25

Review 2.  Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.

Authors:  Fumikazu Sakai; Takeshi Johkoh; Masahiko Kusumoto; Hiroaki Arakawa; Masahiro Takahashi
Journal:  Int J Clin Oncol       Date:  2012-11-10       Impact factor: 3.402

3.  A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab.

Authors:  Shin-Ya Kawashiri; Atsushi Kawakami; Noriho Sakamoto; Yuji Ishimatsu; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2010-05-18       Impact factor: 2.631

Review 4.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 5.  Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).

Authors:  Adelle S Jee; Tamera J Corte
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

Review 6.  Pulmonary complications of tumor necrosis factor-targeted therapy.

Authors:  Krishna Thavarajah; Peggy Wu; Elisa J Rhew; Anjana K Yeldandi; David W Kamp
Journal:  Respir Med       Date:  2009-02-07       Impact factor: 3.415

7.  Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

8.  Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment.

Authors:  Hirofumi Taki; Yukio Kawagishi; Koichiro Shinoda; Hiroyuki Hounoki; Reina Ogawa; Eiji Sugiyama; Kazuyuki Tobe
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

9.  Association of Single Nucleotide Polymorphisms of PADI4 and HLA-DRB1 Alleles with Susceptibility to Rheumatoid Arthritis-Related Lung Diseases.

Authors:  Seung Taek Song; Song Soo Kim; Ji Young Kim; So Young Lee; Kwangwoo Kim; In Sun Kwon; Ji Na Kim; Won Hong Park; In Seol Yoo; Su-Jin Yoo; Jin Hyun Kim; Seong Wook Kang; Seung-Cheol Shim
Journal:  Lung       Date:  2016-07-02       Impact factor: 2.584

Review 10.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.